Skip to main content

Novartis Value Stock - Dividend - Research Selection


ISIN: CH0012005267, WKN: 904278

Market price date: 27.05.2021
Market price: 88,48 USD

Novartis Fundamental data and company key figures of the share

Annual reports in USD
Key figures 18-02-2021
Cash flow
Net operating cash flow 13.650.000.000
Capital Expenditures -2.497.000.000
Free cash flow
Balance sheet
Total Equity 56.598.000.000
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted) 3,520
Diluted shares outstanding
Net sales/revenue 49.898.000.000

Fundamental ratios calculated on: 27-05-2021

Key figures 27-05-2021
Cash flow
P/C 14,74
P/FC 17,91
Balance sheet
Income statement
Div. Yield3,47%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization201.234.120.704,00 USD
Raw Data SourceIFRS in Millionen USD
Stock Split2019-04-09,1116.0000/1000.0000; 2000-05-12,2.0000/1.0000; 2000-05-11,2.0000/1.0000

Description of the company

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,